Skip to main content

Advertisement

SpringerLink
Log in

Antidiabetic effects of hydroxychloroquine in two Japanese patients with systemic lupus erythematosus

  • Case Report
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Hydroxychloroquine (HCQ), an antimalarial drug, is recommended for all patients with systemic lupus erythematosus (SLE), and is widely used around the world. HCQ has various beneficial effects, including antidiabetic effects but was unavailable in Japan until gaining approval for SLE treatment in 2015. We present herein the cases of two Japanese women with SLE and diabetes mellitus (DM) who were treated using HCQ and achieved reductions in glycosylated hemoglobin (HbA1c). A 48 year-old Japanese woman with SLE and DM (patient 1) received oral HCQ at 200 mg/day for the treatment of lupus nephritis. HbA1c levels decreased from 7.2–6.2% after 14 months of HCQ without any loss of body weight or alterations in doses of glucocorticoid or hypoglycemic agents. A 64 year-old Japanese woman with SLE and DM (patient 2) received oral HCQ at 200 mg and 400 mg on alternate days for the treatment of erythema. She also received intensive insulin therapy. HCQ drastically reduced both HbA1c levels, from 10.3 to 7.5%, and the insulin doses required without altering the doses of glucocorticoid or hypoglycemic agents, although body weight increased slightly. No episodes of hypoglycemia were seen in either patient. HCQ can achieve antidiabetic effects in Japanese SLE patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45.

    Article  CAS  Google Scholar 

  2. Thong B, Olsen NJ. Systemic lupus erythematosus diagnosis and management. Rheumatology. 2017. https://doi.org/10.1093/rheumatology/kew401.

    Article  PubMed  Google Scholar 

  3. Kishimoto M, Deshpande GA, Yokogawa N, Buyon JP, Okada M. Use of hydroxychloroquine in Japan. J Rheumatol. 2012;39:1296.

    Article  Google Scholar 

  4. Yokogawa N, Eto H, Tanikawa A, Ikeda T, Yamamoto K, Takahashi T, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol. 2017;69:791–9.

    Article  CAS  Google Scholar 

  5. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298:187–93.

    Article  CAS  Google Scholar 

  6. Solomon DH, Garg R, Lu B, Todd DJ, Mercer E, Norton T, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res. 2014;66:1246–51.

    Article  CAS  Google Scholar 

  7. Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc. 2016. https://doi.org/10.1161/JAHA.115.002867.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37:1136–42.

    Article  CAS  Google Scholar 

  9. Chen YM, Lin CH, Lan TH, Chen HH, Chang SN, Chen YH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology. 2015;54:1244–9.

    Article  CAS  Google Scholar 

  10. Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology. 2008;47:378–9.

    Article  CAS  Google Scholar 

  11. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004. https://doi.org/10.1097/01.asn.0000108969.21691.5d.

    Article  PubMed  Google Scholar 

  12. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550–8.

    Article  CAS  Google Scholar 

  13. Mercer E, Rekedal L, Garg R, Lu B, Massarotti EM, Solomon DH. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012;14:R135.

    Article  CAS  Google Scholar 

  14. Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58:2336–43.

    Article  CAS  Google Scholar 

  15. Rekedal LR, Massarotti E, Garg R, Bhatia R, Gleeson T, Lu B, et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 2010;62:3569–73.

    Article  CAS  Google Scholar 

  16. Wondafrash DZ, Desalegn TZ, Yimer EM, Tsige AG, Adamu BA, Zewdie KA. Potential effect of hydroxychloroquine in diabetes mellitus: a systematic review on preclinical and clinical trial studies. J Diabetes Res. 2020. https://doi.org/10.1155/2020/5214751.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018;38:653–71.

    Article  CAS  Google Scholar 

  18. Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab. 2014;5:77–85.

    Article  CAS  Google Scholar 

  19. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–33.

    Article  CAS  Google Scholar 

  20. Nishimoto S, Fukuda D, Sata M. Emerging roles of Toll-like receptor 9 in cardiometabolic disorders. Inflamm Regen. 2020;40:18.

    Article  CAS  Google Scholar 

  21. Liu M, Peng J, Tai N, Pearson JA, Hu C, Guo J, et al. Toll-like receptor 9 negatively regulates pancreatic islet beta cell growth and function in a mouse model of type 1 diabetes. Diabetologia. 2018;61:2333–43.

    Article  CAS  Google Scholar 

  22. Escárcega RO, García-Carrasco M, Fuentes-Alexandro S, Jara LJ, Rojas-Rodriguez J, Escobar-Linares LE, et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev. 2006;6:48–53.

    Article  Google Scholar 

  23. Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76:848–54.

    Article  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge the work of past and present members of our department.

Author information

Authors and Affiliations

  1. Department of Rheumatology, University of Yamanashi Hospital, 1110 Shimokato, Chuo-shi, Yamanashi, 409-3898, Japan

    Shunichiro Hanai, Yoshiaki Kobayashi, Ryosuke Ito, Kei Kobayashi & Daiki Nakagomi

  2. Department of Diabetology and Endocrinology, University of Yamanashi Hospital, 1110 Shimokato, Chuo-shi, Yamanashi, 409-3898, Japan

    Masashi Ichijo

Authors
  1. Shunichiro Hanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiaki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masashi Ichijo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryosuke Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kei Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daiki Nakagomi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shunichiro Hanai.

Ethics declarations

Conflict of interest

The authors state that they have no conflicts of interest.

Informed consent

Written informed consent was obtained from the patient by the corresponding author. The signed consent forms are retained by the corresponding author. We anonymized the patient’s details as much as possible.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hanai, S., Kobayashi, Y., Ichijo, M. et al. Antidiabetic effects of hydroxychloroquine in two Japanese patients with systemic lupus erythematosus. Diabetol Int 13, 447–451 (2022). https://doi.org/10.1007/s13340-021-00544-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-021-00544-z

Keywords

Search

Navigation